{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:06:56Z","timestamp":1784567216874,"version":"3.55.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Science","doi-asserted-by":"crossref","award":["UL1TR001878"],"award-info":[{"award-number":["UL1TR001878"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007929","name":"Institute for Translational Medicine and Therapeutics\u2019","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007929","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R25 DK108711"],"award-info":[{"award-number":["R25 DK108711"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biologic therapy has improved care for patients with inflammatory bowel disease (IBD), but adherence is often suboptimal, and a gap in care is lack of engagement between visits. We evaluated the effect of a behaviorally-informed remote text monitoring program on outcomes and adherence among patients with IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with IBD and receiving biologics through home health or self-injection were individually randomized 1:1 to control (usual care) or intervention (remote monitoring), stratified by medication type (home infusion vs. injection). The 4-month intervention included the following components via text message: (1) biologic dose reminders, (2) medication adherence check-ins after each dose, (3) weekly symptom check-ins with escalation to the patient\u2019s care team if above threshold, and (4) feedback to an identified support partner (when applicable). The primary outcome was change in quality of life via the Short Inflammatory Bowel Disease Questionnaire (SIBDQ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>150 patients were enrolled; 148 completed the study, and 144 were analyzed for the survey outcomes (73 control, 71 intervention). The mean age was 38.9, 52.7% were female, and 81.1% were White. No significant differences were found between arms for the change in median score from baseline to end of study for the SIBDQ, MARS-5, or patient satisfaction surveys. Medication adherence remained high across both arms, and there was no significant difference in the proportion of days covered for infusion or injection between arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Remote monitoring was feasible with high patient satisfaction, but there was no improvement in quality of life or medication adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>clinicaltrials.gov NCT04388865<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag076","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:40:42Z","timestamp":1783438842000},"source":"Crossref","is-referenced-by-count":0,"title":["Remote monitoring to improve engagement for patients with inflammatory bowel disease: a randomized clinical trial"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-4739","authenticated-orcid":false,"given":"Shivan J","family":"Mehta","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]},{"name":"Population Health Lab, Center for Health Care Transformation & Innovation, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]},{"name":"Population Health Lab, Center for Health Care Transformation & Innovation, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Brophy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]},{"name":"Population Health Lab, Center for Health Care Transformation & Innovation, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Reitz","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]},{"name":"Population Health Lab, Center for Health Care Transformation & Innovation, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K","family":"Snider","sequence":"additional","affiliation":[{"name":"Population Health Lab, Center for Health Care Transformation & Innovation, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Bewtra","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"2026072012500587300_otag076-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8553(01)00002-4","article-title":"Epidemiology of inflammatory bowel disease","volume":"31","author":"Loftus","year":"2002","journal-title":"Gastroenterol Clin North Am"},{"key":"2026072012500587300_otag076-B2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"2026072012500587300_otag076-B3","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2026072012500587300_otag076-B4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2026072012500587300_otag076-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ibd\/izz104","article-title":"The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & Colitis Foundation","volume":"26","author":"Park","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026072012500587300_otag076-B6","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.14309\/ajg.0000000000000750","article-title":"Home infliximab infusions are associated with suboptimal outcomes without cost savings in inflammatory bowel diseases","volume":"115","author":"Giese-Kim","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2026072012500587300_otag076-B7","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/ibd\/izy102","article-title":"Nonadherence to biologic therapies in inflammatory bowel disease","volume":"24","author":"Wentworth","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026072012500587300_otag076-B8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ajg.2017.438","article-title":"Defining an optimal adherence threshold for patients taking subcutaneous anti-TNFs for inflammatory bowel diseases","volume":"113","author":"Govani","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026072012500587300_otag076-B9","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2013.10.019","article-title":"Evaluation of the Patient-Reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases","volume":"12","author":"Kappelman","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072012500587300_otag076-B10","first-page":"2262","article-title":"Measurement of inflammatory bowel disease symptoms: reliability of an abbreviated approach to data collection","volume":"21","author":"Henao","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2026072012500587300_otag076-B11","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1055\/a-2154-9172","article-title":"A digital health intervention to improve the clinical care of inflammatory bowel disease patients","volume":"14","author":"Chugh","year":"2023","journal-title":"Appl Clin Inform"},{"key":"2026072012500587300_otag076-B12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.14309\/ajg.0000000000001545","article-title":"Digital health technologies for remote monitoring and management of inflammatory bowel disease: a systematic review","volume":"117","author":"Nguyen","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2026072012500587300_otag076-B13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.cgh.2014.02.022","article-title":"How to help gastroenterology patients help themselves: leveraging insights from behavioral economics","volume":"12","author":"Mehta","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072012500587300_otag076-B14","doi-asserted-by":"crossref","first-page":"e2529825","DOI":"10.1001\/jamanetworkopen.2025.29825","article-title":"Behavioral economic framing for enrollment and retention of patients in remote blood pressure monitoring: a randomized clinical trial","volume":"8","author":"Mehta","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026072012500587300_otag076-B15","doi-asserted-by":"crossref","first-page":"e2028328","DOI":"10.1001\/jamanetworkopen.2020.28328","article-title":"Effect of remote monitoring on discharge to home, return to activity, and rehospitalization after hip and knee arthroplasty: a randomized clinical trial","volume":"3","author":"Mehta","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026072012500587300_otag076-B16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(17)31327-2","article-title":"Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial","volume":"390","author":"de Jong","year":"2017","journal-title":"Lancet"},{"key":"2026072012500587300_otag076-B17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41395-018-0272-8","article-title":"A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD)","volume":"114","author":"Cross","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2026072012500587300_otag076-B18","first-page":"CD014821","article-title":"Remote care through telehealth for people with inflammatory bowel disease","volume":"5","author":"Gordon","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026072012500587300_otag076-B19","first-page":"1571","article-title":"The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"2026072012500587300_otag076-B20","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/bcp.14193","article-title":"The Medication Adherence Report Scale: a measurement tool for eliciting patients\u2019 reports of nonadherence","volume":"86","author":"Chan","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2026072012500587300_otag076-B21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/ibd\/izaa056","article-title":"Utility of the MARS-5 in assessing medication adherence in IBD","volume":"27","author":"Stone","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026072012500587300_otag076-B22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/MIB.0b013e31827febd1","article-title":"Development and testing of a new instrument to measure patient satisfaction with health care in inflammatory bowel disease: the CACHE Questionnaire","volume":"19","author":"Casellas","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2026072012500587300_otag076-B23","first-page":"1","article-title":"On the way to health","volume":"17","author":"Asch","year":"2012","journal-title":"LDI Issue Brief"},{"key":"2026072012500587300_otag076-B24","first-page":"1070","article-title":"An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index","volume":"20","author":"Bewtra","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026072012500587300_otag076-B25","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/j.1572-0241.2001.04682.x","article-title":"The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis","volume":"96","author":"Jowett","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"2026072012500587300_otag076-B26","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.14309\/ajg.0000000000002254","article-title":"Electronic health record burden among gastroenterology providers associated with subspecialty and training","volume":"118","author":"Bali","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026072012500587300_otag076-B27","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.14309\/ajg.0000000000003598","article-title":"Dissatisfaction and barriers in electronic health record use for patients with inflammatory bowel disease: a nationwide survey of major IBD centers","volume":"120","author":"Saleh","year":"2025","journal-title":"Am J Gastroenterol"}],"container-title":["Crohn\u2019s &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag076\/68709022\/otag076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag076\/68709022\/otag076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag076\/68709022\/otag076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:50:16Z","timestamp":1784566216000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag076\/8726265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag076","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"otag076"}}